Rexulti

News

Elderly woman holds her head in her hands; black and white image

Axsome breaks new ground in Alzheimer's with Auvelity OK

Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.

News

BioXcel shares rise on result of Alzheimer’s drug probe

Shares in BioXcel Therapeutics rose more than 31% in early trading today after the biotech said an independent audit of a phase 3 trial of its Alzheimer’s disease therapy

News

Lilly's 'triple G' retatrutide aces crucial obesity trial

Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks